Back to Search
Start Over
Clinical course and prognosis of patients with lung cancer who develop anticancer therapy-related pneumonitis.
- Source :
-
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 Jun; Vol. 147 (6), pp. 1857-1864. Date of Electronic Publication: 2021 Jan 02. - Publication Year :
- 2021
-
Abstract
- Background: Pneumonitis can be triggered by anti-cancer therapies: cytotoxic chemotherapy, tyrosine kinase inhibitors, and immune checkpoint inhibitors. There are few treatment options for patients who develop such pneumonitis and their treatment including chemotherapy is generally difficult thus would limit patient's prognosis. In this study, we investigated the clinical course of patients with lung cancer who developed anti-cancer therapy-related pneumonitis.<br />Patients and Methods: We retrospectively examined data of patients who had developed pneumonitis triggered by anti-cancer agents and required hospitalization from January 2014 to March 2019 and analyzed their subsequent clinical course and prognosis.<br />Results: The median age of the 58 study patients was 68 years and 82.8% were men. The median interval between first receiving the responsible agent and drug-induced pneumonitis was 7.4 weeks. Approximately 38% of patients were subsequently able to receive some anti-cancer therapy. The median post-pneumonitis overall survival (OS) from commencement of anti-cancer treatment was 13.2 months. No significant differences were found in survival time between treatment agents. However, patients who received some anticancer therapy after pneumonitis had significantly longer survival times than those did not (HR = 4.11, p = 0.0003) and patients who took longer to develop pneumonitis had a longer survival (HR = 2.28, p = 0.0148). Multivariate analysis revealed that short interval to onset and no post-pneumonitis anticancer therapy were independent predictors of short survival.<br />Conclusion: Although patients who developed pneumonitis had relatively short survival times, the interval between initial therapy and pneumonitis had survival impact. Survival can be prolonged by administering further cancer treatment after resolution of pneumonitis.
- Subjects :
- Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal administration & dosage
Antibodies, Monoclonal adverse effects
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Carcinoma, Non-Small-Cell Lung diagnosis
Carcinoma, Non-Small-Cell Lung mortality
Carcinoma, Non-Small-Cell Lung pathology
Female
Humans
Japan epidemiology
Lung Neoplasms diagnosis
Lung Neoplasms mortality
Lung Neoplasms pathology
Male
Middle Aged
Pneumonia mortality
Pneumonia pathology
Prognosis
Protein Kinase Inhibitors administration & dosage
Protein Kinase Inhibitors adverse effects
Retrospective Studies
Survival Analysis
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols adverse effects
Carcinoma, Non-Small-Cell Lung drug therapy
Lung Neoplasms drug therapy
Pneumonia chemically induced
Pneumonia diagnosis
Subjects
Details
- Language :
- English
- ISSN :
- 1432-1335
- Volume :
- 147
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Journal of cancer research and clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 33387034
- Full Text :
- https://doi.org/10.1007/s00432-020-03478-2